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Introduction: Breast cancer is the most commonly diagnosed cancer worldwide. With the challenges of cancer treatment in 
developing countries there is a need for a systematic and methodical approach to treatment in resource-limited settings.
Objective: To retrospectively evaluate the profile of breast cancer patients irradiated with curative intent and discuss the 
therapeutic outcomes, and to compare this cohort with the available developed-world data.
Methods: A retrospective cohort of 689 breast cancer patients from 2010–2014 at Tygerberg Hospital, Western Cape Province 
was analysed. The best-case disease-free survival was calculated at five years and compared with the SEER database. Various 
prognostic factors were calculated by univariate and multivariate analysis.
Results: The five-year best-case disease-free survival (DFS) for Stage I is 94.7% (95% CI 68–99) and for Stage IIIC, 71.3% (95% CI 
39–88).
Conclusion: Outcomes of treatment at this institution are comparable to data reported in first-world countries. As two-
dimensional radiotherapy compares with most Cobalt specifications, the majority of breast cancer patients in sub-Saharan Africa 
can be treated efficiently with Cobalt-type technology.
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Introduction
Breast cancer is the most commonly diagnosed cancer amongst 
women of all races in South Africa. According to information from 
the South African cancer registry 6 849 new breast cancer cases 
were reported in 2011. This constitutes 20% of total cancer cases.1
South Africa is a bridge model between developed and 
developing countries as it has the availability of better 
infrastructure, pathology services, staging and therapeutic 
modalities, yet still faces high patient to radiotherapy machine 
and medical personnel ratios. Another confounding factor that 
bridges the South African environment to the rest of sub-Saharan 
Africa is the presentation of patients with advanced disease, as 
well as socio-economic difficulties and poor health-seeking 
behaviour. Furthermore the National Institute of Health Public 
Access report reveals the increasing similarity of breast cancer 
regarding patient profile throughout Africa.2
Many studies over the last 20 years confirmed the advantage of 
adjuvant radiotherapy in the management of curable invasive 
breast cancer.3–6 Infrastructure problems in Africa make it 
challenging to offer quality radiotherapy and gain its benefit.
Objectives
The primary objective of this study was to retrospectively 
evaluate the patient profile, at Tygerberg hospital and establish 
disease-free survival (DFS). Outcomes were then compared with 
those in the Surveillance, Epidemiology and End result Program 
(SEER) database (Figure 1).
Methods
This retrospective descriptive study investigated breast cancer 
patients at Tygerberg hospital (TBH) irradiated with curative 
intent over a five-year period (2010–2014). The local protocol is 
for chest wall or the intact breast to be treated with tangential 
fields. Where supraclavicular and axillary irradiation was 
indicated, field matches with half-beam block techniques were 
used. Energy preference was 6 MV and higher energies were 
used only for separations of 24 cm and higher.
Stage T1, T2 less than 3  cm and N0 disease were treated with 
tumour excision (TE), followed by irradiation. Factors influencing 
this decision were tumour site, size, histological type, grade, in situ 
disease, size of breast and patient preference. Post-mastectomy 
radiotherapy was recommended for T3, T4, patients with four or 
more axillary nodes and young patients with up to three nodes. 
Other poor prognostic indicators—grade 3, oestrogen receptor 
negative, lymphovascular invasion and lobular histology—were 
taken into account in radiotherapy decision-making.
Lymph nodes were irradiated to any sentinel-confirmed or FNA-
positive node. Fields included supraclavicular, infraclavicular and 
intramammary nodes. Levels 1, 2 and 3 were added if not 
surgically addressed.
The population assessed were patients older than 18  years, 
presenting with Stage IB–IIIC breast cancer, post-mastectomy or 
breast-conserving therapy and indicated for radiotherapy. 
Patients were identified by searching the departmental 
electronic database and validated with the TBH breast cancer 
registry. Data were collected from files and the electronic hospital 
report system. Patients with incomplete medical records and 
second primary tumours were excluded. Ethical approval was 
obtained from the Health Research Ethics Committee of the 
Faculty of Health Sciences, Stellenbosch University.
A cohort of 689 patients was evaluated for age, race, HIV status, 
stage, histology, pathological grading, molecular subtype, type 
of surgery, waiting time, and 2Dimensional (2D) vs. 3Dimensional 
(3D) radiotherapy planning. Indications for 2D planning are 
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patients who had undergone a mastectomy, and had no 
indication for supraclavicular nodal irradiation. Disease-free 
survival (DFS) by best- and worse-case scenario was statistically 
calculated.
Statistical considerations
The statistical consulting service at the Biostatistics Unit within 
the Centre for Evidence Based Health Care (CEHBC) assisted with 
the analysis of this study through support from university 
funding for local research. Data were analysed using STATA 14® 
(StataCorp, College Station, TX, USA). A sample-size calculation 
was not required, as all new patients diagnosed over the period 
2010–2014 (2 223 patients) were included, and generalised to 
that cohort of 689 patients.
Simple descriptive statistics was used to describe the data. Data 
were reported as mean and standard deviation or median and 
interquartile range where appropriate. Normality of data was 
tested using both qualitative (graphs) and quantitative methods 
(test of normality). An appropriate parametric or non-parametric 
test was used with a significant p-value of 0.05. Survival analysis 
(Kaplan–Meier survival analysis) was performed for five-year 
recurrence-free survival and overall survival. Patients with 
censored data were assumed not to have recurrent disease (best-
case scenario). A worst-case scenario was also used (loss to 
follow-up assumed to have the outcome of interest) in the 
analysis. Relevant outcomes and measures of effect are reported 
with 95% confidence intervals. No missing data were added.
Results
Table 1 details the study characteristics by different prognostic 
groups. Mixed-race women made up 63% of the total of this 
cohort, consistent with the demographics of the drainage area of 
the institution, and 4.9% were HIV-positive. The majority of the 
patients were stage IIB to IIIB (65.8%). The most common 
histology was with an infiltrating ductal carcinoma (84.6%), 
which was mostly grade 2 (43.9%). The patients who qualified for 
2D radiotherapy comprised 59.3%. The remaining patients 
(40.3%) were planned using 3D conformal radiotherapy. 
Mastectomy was offered to 69.2% of the patients. The waiting 
time from surgery to radiotherapy was longer than 90 days, for 
60.3% of patients.
Best- and worst-case analysis for five-year disease-free survival 
(DFS) is given in Table 2. Stage I best-case DFS was 94.7% (with 
95% CI 68–99). Stage IIA best-case scenario was 92.1% (95% CI 
85–95); 88.6% for Stage IIIA; 60% for IIIB and 71.3% for IIIC. There 
Figure 1: DFS over time up to 70 months.
Table 1: Proportions within different prognostic groups
Characteristics n (%) Mortality 
n (%)
Local 
recurrence 
n (%)
Metastasis 
n (%)
Age (years):
20–34 26 (3.8) 2 (7.6) 1 (3.8) 5 (19.2)
35–44 112 (16.3) 3 (2.6) 6 (5.3) 15 (12.3)
45–54 198 (28.9) 5 (2.53) 7 (3.5) 22 (11.1)
55–64 208 (30.3) 4 (1.9) 7 (3.3) 19 (9.1)
65–74 114 (16.6) 2 (1.7) 3 (2.6) 5 (4.3)
> 75 27 (3.9) – – –
Race:
European 168 (26.9) 2 (1.1) 4 (2.3) 16 (9.5)
Mixed 393 (63) 12 (3.3) 15 (3.8) 40 (10.1)
Black 54 (8.6) 1 (1.8) 4 (7.4) 5 (9.2)
Indian 5 (0.8) – – –
Unknown 3 (0.4) – – –
HIV status:
Positive 25 (4.9) – 1 (4) 5 (20)
Negative 483 (95.1) 12 (2.4) 18 (3.7) 53 (10.7)
Stage:
I 33 (5) – – 1 (3)
IIA 168 (25.5) 1 (0.6) 4 (2.3) 8 (4.7)
IIB 169 (25.7) 2 (1.1) 3 (1.7) 15 (8.8)
IIIA 95 (14.4) 3 (3.1) 2 (2.1) 4 (4.2)
IIIB 169 (25.7) 9 (5.3) 12 (7.1) 33 (19.5)
IIIC 23 (3.5) 1 (4.3) 2 (8.7) 3 (13)
Histology:
Infiltrating ductal 569 (84.6) 14 (2.4) 23 (4) 61 (10.7)
Lobular 34 (5) 1(2.9) – 2 (5.8)
Medullary 7(1) 1 (14.2) – –
Mucinous 22 (3.2) – – –
Poorly differen-
tiated
5 (0.7) – – –
Non-specific type 14 (2) – 1 (7.1) 2 (14.2)
Other 21 (3.1) – – –
Pathological grading:
I 121 (21.9) 1 (0.8) 3 (2.4) 7 (5.7)
II 242 (43.9) 5 (2) 8 (3.3) 26 (10.7)
III 188 (34.1) 7 (2.3) 13 (6.9) 27 (14.3)
Molecular subtype:
Luminal A 291 (43.8) 3 (1) 8 (2.7) 27 (9.2)
Luminal B (Her 
neg.)
92 (13.8) 1 (1) 3 (3.2) 11 (11.9)
Luminal B (Her 
pos.)
169 (25.4) 7 (4.1) 5 (2.9) 15 (8.8)
Basal like 107 (16.1) 5 (4.6) 7 (6.5) 11 (10.2)
Unclassified 5 (0.75) – – –
Waiting time
<= 90 days 252 (39.2) 4 (1.5) 8 (3.1) 24 (9.5)
> 90 days 384 (60.3) 12 (3.1) 15 (3.9) 37 (9.6)
Planning:
Sim mark up (2D) 399 (59.3) 11 (2.7) 14 (3.5) 40 (10)
CT Plan (3D) 272 (40.6) 4 (1.4) 9 (3.3) 23 (8.4)
(Continued)
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were no differences in outcome for waiting times more vs. less 
than 90 days. Outcomes for 2D vs. 3D planning are comparable, 
82.8 vs. 77.9%.
When looking at the multivariate analysis we found age, Stage 
IIIB, and tumour excision (TE) with sentinel node significantly 
impacted outcome (Table 3).
The arbitrary cut-off for waiting times from surgery to adjuvant 
radiotherapy of 90 days revealed no differences in outcome.
Discussion
The Breast Health Global initiative (BHGI) derived guidelines for 
the implementation of breast cancer healthcare in low- and 
middle-income countries, where they classified the level of 
resources from these countries into basic, limited, enhanced and 
maximal. Therefore clinical practice will be dependent on which 
category an institution falls into. It is expected that better 
outcomes in practice would be associated with better resources.7,8 
In our institution outcomes for breast cancer treated with 
curative intent are very similar to outcomes in the first-world 
scenario.
We found stage at presentation in our cohort to be similar to the 
SEER data.2
Ideally all patients should be planned on a three-dimensional 
(3D) planning system.9 Two-dimensional (2D) planning is used in 
most of the low-income countries where radiotherapy is 
available. At our institution only 40.5% of breast patients 
underwent 3D planning and the remainder were treated using 
2D techniques. The 2D plans are adequate for small patients who 
have had a mastectomy and require chest wall radiotherapy 
only, as the dose distribution and normal tissue dose volume 
histograms (DVH) compare well with those of a 3D plan.10 It was 
notable that there is a lower incidence of breast-conserving 
surgery, due to many patients presenting with more advanced 
disease—but outcomes were still comparable by stage.2
The use of linear accelerators (LINACS) with 3D conformal 
capability is the gold standard, but the availability and stability 
of electricity supply, quality assurance, maintenance and human 
resources remain a challenge. Munshi et al., based in Mumbai, 
compared the quality of life of patients treated on Cobalt-60 
machines versus those treated on linear accelerators and found 
no difference in outcome.11 Development of Cobalt-60 
technology in modern radiation therapy is slowly making space 
for more conformal treatment.12 Despite the growing pressures 
to abandon use of Cobalt-60 radiotherapy machines, their 
reliability and relatively easier maintenance remain an attractive 
option for developing countries in sub-Saharan Africa.13,14
Our study indicates comparable survival and DFS when 
compared with international outcomes by stage, despite the 
more advanced presentation of the disease and higher use of 2D 
planning.
Characteristics n (%) Mortality 
n (%)
Local 
recurrence 
n (%)
Metastasis 
n (%)
Type of surgery:
Tumour excision 
(TE) only 
3 (0.4) 1 (33.3) – 1 (33.3)
TE and sentinel 
node
125 (18.3) – 4 (3.2) 6 (4.8)
TE and axillary 
dissection
81 (11.8) 2 (2.4) 1 (1.2) 7 (8.6)
Simple mastecto-
my (SM)
11 (1.6) – – –
SM and sentinel 
node
81 (11.8) – – 2 (2.4)
SM and axillary 
dissection
13 (1.9) – 1 (7.6) 1 (7.6)
Modified radical 
mastectomy
368 (53.9) 13 (3.5) 18 (4.8) 49 (13.3)
Table 1: (Continued) Table 2: Disease-free survival (DFS) by best- and worse-case scenarios
Prognostic factor Five-year best-case 
analysisDFS (95% CI)
Five-year worse-
case analysisDFS 
(95% CI)
Age at diagnosis:
20–34 76% (46–90) [at 
56 months]
53% (29–72) [at 
56 months]
34–44 76.4% (63–85) 64.4% (51–74)
45–54 78.1% (66–86) 67.7% (54–77)
55–64 82.8% (74–88) 68% (59–76)
65–74 85.1% (70–92) 72% (58–82)
75–84 – 44% (9–76%)
> 84 – –
Stage:
I 94.7% (68–99) 90.7% (67–97)
IIA 92.1% (85–95) 74.4% (60–84)
IIB 84.2% (74–90) 71.3% (61–79)
IIIA 88.6% (74–95) 75.1% (61–84)
IIIB 60% (46–71) 44.6% (32–56)
IIIC 71.3% (39–88) 58.9% (29–79)
HIV status:
Positive 74.3% (48–88) [at 
58 months]
51.5% (28–70) [at 
58 months]
Negative 79.4% (73–84) 67.1% (60–72)
Waiting time:
<= 90 days 82.8% (75–88) 69.1% (61–75)
> 90 days 81.4% (75–86) 68.2% (61–74)
Planning:
Sim mark up (2D) 82.8% (77–87) 66.6% (59–72)
CT Plan (3D) 77.9% (67–85) 67.3% (56–76)
Type of surgery:
Tumour excision (TE) 
only 
– –
TE and sentinel node 89.9% (79–95) 82.7% (70–90)
TE and axillary dissec-
tion
82.5% (63–92) 65.9% (45–80)
Simple mastectomy 
(SM)
– 88.8% (43–98) [at 
54 months]
SM and sentinel node 96.2% (85–99) 86% (73–92)
SM and axillary dis-
section
90% (47–98) 81.8% (44–95)
Modified radical mas-
tectomy
74.7% (67–80) 58.4% (51–65)
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techniques alone, similar to many centres in sub-Saharan Africa. 
Basic Cobalt machines will thus be able to successfully treat the 
majority of breast cancer patients in need of radiotherapy.
Disclosure statement – No potential conflict of interest was 
reported by the authors.
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The strengths of this study include a large patient cohort, where 
treatment was consistent.
The study weakness is a single-institution, retrospective study.
Conclusion
Patient profiles in Western Cape can be expected to be similar to 
those described elsewhere in Africa. If the best-case scenario is 
accepted in this study, our institutional outcomes compare well 
with first-world results, as seen in the SEER report.2 A large 
number of patients present with locally advanced cancer, and 
are therefore less likely to undergo breast-conserving surgery. 
Many of these patients were treated successfully with 2D 
Table 3: Measure of effect hazard ratio (HR) for disease-free survival 
(DFS)
*Forwards stepwise modelling included only age and stage. Collinearity 
was found between HIV status and age.
**Indicates significant results at p < 0.05.
Prognostic factor Univariate HR for 
DFS (95% CI)
Multivariate* HR for 
DFS (95% CI)
Age 0.97 (0.95–0.99)** 0.97 (0.95–0.99)**
Stage:
I 1 1
IIA 1.93 (0.24–15.15) 2.03 (0.25–15.92)
IIB 3.39 (0.44–25.64) 2.36 (0.44–25.41)
IIIA 2.24 (0.25–18.86) 2.12 (0.25–17.83)
IIIB 10.63 (1.45–77.48)** 10.45 (1.43–76.16)**
IIIC 6.61 (0.73–59.40) 6.14 (0.68–55.15)
HIV status:
Negative 1 –
Positive 2.49 (0.99–6.22) –
Waiting Time
<= 90 days 1 –
> 90 days 0.73 (0.46–1.18) –
Planning:
Sim mark up (2D) 1 –
CT Plan (3D) 0.88 (0.55–1.41) –
Type of surgery:
Tumour excision (TE) 
only 
1 –
TE and sentinel node 0.09 (0.01–0.74)** –
TE and axillary dissec-
tion
0.1 (0.01–0.9)** –
Simple mastectomy 
(SM)
– –
SM and sentinel node 0.04 (0.003–0.44)** –
SM and axillary dis-
section
0.09 (0.005–1.47) –
Modified radical mas-
tectomy
0.23 (0.03–1.72) –
